Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.
The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first-and-only dual A2a/A2b adenosine receptor antagonist in the clinic.
Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options.
